PERIPHERAL T-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Clinical trials for PERIPHERAL T-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED explained in plain language.
Never miss a new study
Get alerted when new PERIPHERAL T-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED trials appear
Sign up with your email to follow new studies for PERIPHERAL T-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug Q702 aims to boost immune system against blood cancers
Disease control Recruiting nowThis early-stage trial tests a new drug called Q702 in people with certain blood cancers or related diseases that have not responded to other treatments. The drug works by helping the immune system attack cancer cells and supporting normal blood cell production. The study will ch…
Matched conditions: PERIPHERAL T-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 17, 2026 10:36 UTC
-
New hope for rare blood cancer: targeted drug soquelitinib faces standard care in phase 3 trial
Disease control Recruiting nowThis study tests a new drug called soquelitinib against standard treatments for people with certain types of T-cell lymphoma that have come back or not responded to therapy. About 150 adults will be randomly assigned to receive either soquelitinib or a standard single-agent chemo…
Matched conditions: PERIPHERAL T-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Phase: PHASE3 • Sponsor: Corvus Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 17, 2026 10:27 UTC
-
Could a stem cell transplant keep T-Cell lymphoma away longer?
Disease control Recruiting nowThis study compares two approaches for people with peripheral T-cell lymphoma who are in complete remission after initial treatment: either high-dose chemotherapy followed by a transplant of their own stem cells, or simply watching and waiting. The goal is to see if the transplan…
Matched conditions: PERIPHERAL T-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Phase: PHASE3 • Sponsor: Eastern Cooperative Oncology Group • Aim: Disease control
Last updated May 14, 2026 12:06 UTC
-
Cancer-Killing virus trial opens for tough lymphomas
Disease control Recruiting nowThis early-stage trial tests a specially modified virus (VSV-hIFNβ-NIS) combined with two immunotherapy drugs (ipilimumab and cemiplimab) in adults with relapsed or refractory T-cell lymphoma. The virus is designed to kill cancer cells while leaving healthy cells alone, and the i…
Matched conditions: PERIPHERAL T-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 14, 2026 12:06 UTC